title: High expression of AT-rich interactive domain 3A (ARID3A) is associated with good prognosis in colorectal carcinoma.
abstract: BACKGROUND
  AT-rich interactive domain 3A (ARID3A) is a member of the ARID family of DNA-binding proteins. Previous reports have shown that ARID3A controls cell growth in a p53-dependent manner. Recently, it has been reported that expression of the ARID3A protein was markedly increased in colon cancer tissue compared with matched normal colonic mucosa. However, little is currently known about the role of ARID3A in colorectal cancer (CRC). The aim of this study was to investigate the clinical significance of ARID3A expression in CRC.
  
  
  METHODS
  We examined ARID3A expression in 690 CRC patients using tissue microarray and immunohistochemistry. Kaplan-Meier analysis and Cox proportional hazard models were used to estimate the impact of ARID3A expression on overall survival.
  
  
  RESULTS
  Of the 690 cases, 195 tumors were strongly positive for ARID3A, 187 were weakly positive, and 308 were negative. ARID3A expression in CRC was significantly correlated with age, degree of differentiation, depth of invasion, lymph node metastasis, distant metastasis, tumor-node-metastasis stage, status of microsatellite instability, and carcinoembryonic antigen levels. The overall survival of CRC patients with strong ARID3A expression was significantly longer than that of patients with weak or negative ARID3A expression. We also performed an additional survival analysis on 388 colon cancer patients and 302 rectal cancer patients. In doing so, a favorable prognostic effect of ARID3A expression was revealed only in the colon cancer group (p = 0.002), not in rectal cancer. Moreover, we showed that the effect of ARID3A on the survival was correlated with p53 status. Using multivariate analysis, we found that strong expression of ARID3A was an independent predictor for better prognosis in CRC.
  
  
  CONCLUSIONS
  Our data suggested that strong expression of ARID3A may predict a good prognosis in patients with CRC.
authors.affiliation: Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea.
authors.forename: Meiying
authors.initials: M
authors.lastname: Song
authors.forename: Hyunki
authors.initials: H
authors.lastname: Kim
authors.forename: Won Kyu
authors.initials: WK
authors.lastname: Kim
authors.forename: Sung Pil
authors.initials: SP
authors.lastname: Hong
authors.forename: Cheolju
authors.initials: C
authors.lastname: Lee
authors.forename: Hoguen
authors.initials: H
authors.lastname: Kim
mesh_terms: D000236:Adenoma / Q000737:chemistry*; D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002272:Carcinoembryonic Antigen / Q000097:blood; D002277:Carcinoma / Q000737:chemistry* / Q000556:secondary; D002648:Child; D003106:Colon / Q000737:chemistry; D003110:Colonic Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000473:pathology*; D004268:DNA-Binding Proteins / Q000032:analysis* / Q000235:genetics; D005260:Female; D006801:Humans; D007413:Intestinal Mucosa / Q000737:chemistry; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D053842:Microsatellite Instability; D008875:Middle Aged; D060787:Neoplasm Grading; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012004:Rectal Neoplasms / Q000737:chemistry* / Q000235:genetics / Q000473:pathology*; D015996:Survival Rate; D014157:Transcription Factors / Q000032:analysis* / Q000235:genetics; D016159:Tumor Suppressor Protein p53 / Q000032:analysis; D055815:Young Adult
chemical_list: C490798:ARID3A protein, human; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D004268:DNA-Binding Proteins; D014157:Transcription Factors; D016159:Tumor Suppressor Protein p53